No dedicated clinical trials have compared denosumab and bisphosphonates for fracture prevention in patients on dialysis.

UBS forecasts that Sandoz will likely achieve the lower end of its 24-26% core EBITDA margin target by 2028. To reach the ...

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

A HEARTBROKEN mum says she “nearly died” hearing her little girl’s diagnosis – after the tot’s face kept swelling following a ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

Compared with oral bisphosphonate use, denosumab use was associated with a 45% lower risk for fractures among patients on dialysis. Cardiovascular risk was 36% higher with denosumab. Among adults ...

Patients with CKD who use antiresorptive drugs for tumor-related disorders or oral corticosteroids may be at increased risk for osteonecrosis of the jaw.

TUESDAY, Jan. 7, 2025 (HealthDay News) -- For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for ...

On World Cancer Day, we got in touch with an Orthopaedic Oncologist who shares the importance of early detection and expert ...

Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

a proposed denosumab biosimilar to Amgen’s PROLIA and XGEVA. GlyCoNex is a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies. The licensee ...